Bristol-Myers Squibb (BMY) has agreed to acquire Medarex (MEDX) for $16/share in cash - about...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Bristol-Myers Squibb (BMY) has agreed to acquire Medarex (MEDX) for $16/share in cash - about $2.4B - saying it is gaining proven antibody discovery technology and rights to an immunotherapy the companies developed. Medarex closed +1.5% to $8.40. (BMY earnings preview)